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Abstract: Allergies are an increasing global public health concern, especially for children and people
living in urban environments. Allergies impair the quality of life of those who suffer from them,
and for this reason, alternatives for the treatment of allergic diseases or reduction in their symptoms
are being sought. The main objective of this study was to compile the studies carried out on probiotics
as a possible therapy for allergies. The most studied allergies on which probiotics have been shown
to have a beneficial effect are rhinitis, asthma, and atopic dermatitis. Most studies have studied
the administration of Lactobacillus and Bifidobacterium spp. in children and have shown beneficial
effects, such as a reduction in hyperreactivity and inflammation caused by allergens and a decrease
in cytokine release, among other beneficial effects. In the case of children, no clear beneficial effects
were found in several studies, and the potential risk from the use of some opportunistic bacteria,
such as probiotics, seems controversial. In the studies that reported beneficial results, these effects
were found to make allergy symptoms less aggressive, thus reducing morbidity in allergy sufferers.
The different effects of the same probiotic bacteria on different patients seem to reinforce the idea
that the efficacy of probiotics is dependent on the microbial species or strain, its derived metabolites
and byproducts, and the gut microbiota eubiosis of the patient. This study is relevant in the context
of allergic diseases, as it provides a broader understanding of new alternatives for the treatment of
allergies, both in children, who are the main sufferers, and adults, showing that probiotics, in some
cases, reduce the symptoms and severity of such diseases.
Keywords: allergic disease; probiotic; atopic dermatitis; rhinitis; gut microbiota
1. Introduction
An allergy is defined as a hypersensitivity reaction caused by an immunological
response to a specific antigen, known as an allergen. Allergens act on innate immune cells.
Repeated contact with an allergen triggers the activation of mast cells and basophils and
the release of allergic mediators, resulting in symptoms ranging from sneezing and itchy
rashes to severe shortness of breath and anaphylaxis [1–3]. Currently, the list of allergic
diseases published by the WHO includes asthma, rhinitis, conjunctivitis, rhinosinusitis,
anaphylaxis, atopic eczema, hives, and angioedema, as well as secondary reactions caused
by drugs, foods, or insects [4].
Today, approximately 1 billion people worldwide suffer from allergies, and these
numbers are estimated to increase to 4 billion in the next 30–40 years [1]. In recent
years, the prevalence of allergic diseases has increased greatly, to the point that 30–40%
of the world’s population now suffers from one or more allergic diseases. It is important
to note that these diseases affect all age groups, but they are more frequently reported
in childhood [5].
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While no determinant risk factors have been identified, it is possible that environ-
mental factors, such as cigarette smoking, air pollution, and exposure to allergens explain
the observed changes in the prevalence of allergic diseases [6]. A common explanation for
the increased prevalence of allergic diseases is the “hygiene hypothesis”, first proposed
in 1989 by Strachan [7], in which it is stated that a lack of exposure in childhood to infectious
agents, symbiotic microorganisms, and parasites increases the child’s susceptibility to these
diseases later in life [6]. Decreased microbial exposure due to improved hygiene, changes
in diet, or increased use of antibiotics may be determinants of an increased prevalence of
allergies [7–9]. Additionally, there is a lot of evidence suggesting that living in rural areas
in childhood has a protective effect against allergic disease, such as atopy, allergic rhinitis,
and asthma [10,11]. This may be related to environment-derived factors, such as contact
with bacterial endotoxins [12], contact with animals [13], or intake of raw or lightly pro-
cessed milk [13,14]. In recent decades, the migration from traditional farming to the urban
environment, increase in processed food intake, lack of contact with animals, and excessive
hygiene has been related to the increase in the incidence of allergic diseases [15,16].
Due to the increase in allergies, their prevention and treatment have become a global
public health priority. For this reason, new alternatives are being sought, one of which
could be the use of probiotics to prevent these diseases and reduce their symptoms [5].
“Probiotic” means “for life”, and probiotics are defined as “Live microorganisms that, when
being administered in appropriate doses, confer a benefit to the health of the host” [5].
The use of probiotics to treat or prevent specific diseases is a branch of microbiology
known as “therapeutic microbiology” [17–20]. Probiotics exert multiple health effects, such
as immunomodulatory agents and activators of host defense pathways, which reduce
morbidity [21]. In the context of allergic disease, the probiotics’ microbiome is essential
for the development of host immune responses. Effective probiotics must be resistant to
bile salts, gastric enzymes, and a low pH, and they cannot cause mucosal inflammation or
infection [22].
The population of microorganisms that inhabits a determined ecological niche of
healthy individuals is termed the intestinal microbiota. Its colonization begins before birth
and matures slowly, until it reaches the adult state at around 3 years of age. The human gut
microbiota establishes a symbiotic relationship with the host and plays a very important
role in human health, because dysbiosis in the gut microbiota often occurs in the presence
of disease [17,20]. The intestinal microbiota constitute a key factor in the development
of an adequate immune response, because the contact between gut bacterial antigens
and the part of the immune system associated with the intestine represents an important
component of the human immune system [17]. The microbiota play a fundamental role
in the development of the human immune system, especially in the first years of life.
Its main role is to intervene in the homeostasis and immunity of the intestine [17].
The main objective of this study is to provide a literature review of the effects of the ad-
ministration of probiotics in the prevention and treatment of allergic diseases. This study is
relevant, because it broadens the knowledge of new alternatives for the treatment of these
diseases in both children and adults, reduction in the symptoms associated with allergies,
and prevention of the occurrence of allergen-caused acute adverse episodes.
2. Methodology
A narrative literature search was conducted up to 10 February 2021 for all the available
literature in the following databases: Web of Science, PubMed, and Scopus. A combination
of the following search terms was applied: “probiotics” and “allergic diseases”; “gut micro-
biota” and “allergic diseases”. The search terms were adjusted to the specific databases
and consisted of a combination of free-text searches. The selection of articles will be limited
to studies published in English and Spanish, with no restrictions on the year of publication,
although the most prominent articles are those published after 2015. A total of 115 articles
were selected and included in the review. The following data on the study characteristics
were extracted from the included records: author and year of publication, type of study,
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probiotics used, dosage and time of administration, type of allergy, and the conclusions
of each study. The authors reviewed the titles and the abstracts. If the abstracts reported
the use of diaries that contained narrative elements, full texts were read, and if the pre-
established eligibility criteria were met, they were included in the review. A narrative
approach containing summary tables and graphs will facilitate the synthesis of the included
studies.
3. Results and Discussion
3.1. Characteristics of Allergic Diseases and Most Common Allergic Diseases
In allergic diseases, there is a disturbance in the balance between T helper (Th)1
and Th2 lymphocytes in favor of Th2 lymphocytes. Th1 lymphocytes are key to infec-
tion, activating macrophages to defend the body primarily against intracellular microbes.
Th2 lymphocytes, on the other hand, activate eosinophils and mast cells and induce the pro-
duction of IgE, which is responsible for allergies. These allergies are caused by the response
of an inappropriate immune response of Th2 lymphocytes to different antigens, including
environmental or food antigens. The activation of this response leads to the secretion of
interleukins (IL)-4, IL-5, and IL-13 and an allergen-specific IgE production, which drives
allergic inflammation [1,10]. Interferon (INF)-γ inhibits Th1 activity by inducing these
cytokine responses, thus maintaining an allergic phenotype [23].
The prevalence of allergic diseases has doubled in the industrialized parts of the world
in the last 25 years [6]. These diseases mainly affect children and young people, but as they
age, the severity and complexity of these diseases increase, resulting in an adverse impact
on their quality life and high costs to the health care system [10,24]. In general terms, ap-
proximately 200–250 million people suffer from food allergies, one-tenth of the population
suffers from drug allergies, and 400 million suffer from rhinitis [24]. Worldwide, 300 mil-
lion people suffer from asthma, and this incidence is expected to increase by 100 million
in 2025 [25]. Food allergies are recognized as the most common immune disorders [26],
and they are considered a world health risk, particularly in developed countries [27].
The major risk factors for the development of food allergies are related to genetics, the en-
vironment, and immune tolerance failure. Additionally, gut microbiota composition and
activity have an important role in immunological development, and thus, gut microbiota
eubiosis is recognized a key factor in preventing food allergies [26,28].
One variable on which these allergic diseases depend is sex. Due to their characteristics
and specific patterns in women, women are more susceptible than men to allergies due
to the ovarian hormones and hyperreactivity of the airways, which may occur during
the menstrual cycle or pregnancy [29,30]. Previous studies showed that a significant
percentage of women with asthma suffer worse symptoms during the perimenstrual
phase [31,32].
Allergic rhinitis (AR) is foremost among the most common allergic diseases. It af-
fects between 10% and 20% of the total population and is therefore the most prevalent
chronic non-communicable disease in the world [33]. However, the prevalence of this
disease is probably underestimated because many patients do not recognize rhinitis as
a disease and therefore do not seek medical advice [34]. The most important allergens that
trigger AR are pollens. AR results from immunoglobulin (IgE)-mediated inflammation
of the nasal mucosa, which is characterized by pruritus, sneezing, rhinorrhea, and nasal
congestion. In addition, AR is a potential risk factor for asthma [24], another common
allergic disease and chronic inflammatory disorder of the airways, which currently affects
some 300 million people worldwide [24,35]. Asthma is a heterogeneous disease, in which
inflammation of the airways occurs and respiratory symptoms, such as wheezing, chest
tightness, and coughing, along with shortness of breath, which varies in duration and
intensity [36].
Urticaria is a disorder with various underlying causes. It is estimated that approxi-
mately 25% of people experience at least one episode of urticaria in their lifetime, but only
3% will develop chronic urticaria [37]. It is characterized by the appearance of hives, lasting
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between 1 and 24 h, and/or angioedema, which can last up to 72 h [24]. The activation of
mast cells located superficially in the skin leads to urticaria, while mast cells in the dermis
are involved in angioedema. Histamine is the main mediator in urticaria and in many cases
of angioedema [24,38].
The most common chronic inflammatory skin disease is atopic dermatitis (AD). The in-
cidence of AD has increased 2- to 3-fold in recent years in industrialized countries [39,40].
In the last 30 years, the prevalence of this disease has increased to 10–20% in children
and 1–3% in adults. This chronic inflammatory skin disease is also known as atopic
eczema, is very pruritic, and is characterized by erythema and oedema. In addition, AD
usually occurs during infancy and childhood [41]. AD may have a mixed IgE-mediated
and non-IgE-mediated mechanism [10]. Atopy manifests as allergic rhinitis, bronchial
asthma, atopic dermatitis, or even food allergies and is defined as the development of
an immediate hypersensitivity reaction to environmental and food antigens due to a ge-
netic predisposition [24,35]. A variant of AD is allergic contact dermatitis (ACD), which
manifests due to a delayed hypersensitivity reaction and is mediated by T-cells in the skin.
In this case, the allergens, which are called “haptens”, are of a low molecular weight and
bind to proteins in the skin, where they become antigenic [42].
Food-origin allergies have a high morbidity, which affects the sufferer’s quality of
life; involve high costs; and, in the case of anaphylaxis, can lead to death. Worldwide, 220–
250 million people may suffer from food-origin allergies [43]. The foods most frequently
implicated in pediatric patients are cow’s milk and eggs. Moreover, milk or egg sensitiza-
tion in children is associated with an increased risk of developing dust mite allergy and
even asthma. In many cases, food allergies are mediated by IgE [10]. In adulthood, the most
common foods implicated in allergies are legumes, nuts, fruits, and crustaceans [43].
Anaphylaxis is the most serious allergic disease and can be fatal. The onset can
be within minutes or even hours and usually affects different body systems. The trig-
gers of anaphylaxis vary with age and geography, and the prevalence is at least 1% [44].
Anaphylaxis is usually IgE-mediated and can be due to food, insect venom, drugs, or
latex [10].
3.2. The Immune System and Probiotics
The human intestinal microbiota constitutes a complex ecosystem that includes, in ad-
dition to bacteria, fungi, Archaea, viruses, and protozoa. The concentration of bacteria
increases from the stomach the duodenum, but it is in the large intestine where it rises
up to 1011–1012 UCF/g [45]. It has been estimated that there are at least 1800 genera and
between 15,000 and 36,000 species of bacteria in the large intestine [17]. Firmicutes and
Bacteroidetes are the main bacterial phyla, followed by Actinobacteria, Proteobacteria,
and Verrucomicrobia. In addition, fungi and protozoa make up approximately 1% of
the species in our gut microbiota [45,46].
“Probiotic” means “for life”, and probiotics are currently used to refer to bacteria that
have beneficial effects on human and animal health [17]. In 2001, the Food and Agriculture
Organization of the United Nations (FAO)/World Health Organization (WHO) defined
them as “live microorganisms which, when administered in adequate amounts, confer
a health benefit on the host” [47]. This definition was corrected in 2014 by the International
Scientific Association for Probiotics and Prebiotics, and it now reads “microorganisms
for which there is scientific evidence of safety and efficacy” and excludes “live cultures
associated with fermented foods for which there is no evidence of a health benefit” [48].
Probiotics contribute various beneficial effects on human health and are used to treat
different infectious and non-infectious diseases. Various effects have been seen in the form
of protection against infections, decreases in irritable bowel symptoms, the inhibition of
Helicobacter pylori growth and viral infections [49], the prevention of cancer, decreases
in gut inflammatory response, and the prevention and/or treatment of allergies, which is
the focus of this review [5].
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It is believed that the administration of beneficial microorganisms may be the key to
improving health and susceptibility to disease, as human organisms and the gut microbiota
establish a symbiotic relationship important for the maintenance of human health [17]. It is
likely that these microbiota organisms have evolved along with our immune system, thus
promoting immune tolerance. This includes the induction of regulatory T cells (Treg) and
the control of Th2 and Th1 balance, which may prevent the development of allergic and
autoimmune diseases [1].
Probiotics can stimulate the immune system compounds secreted or present in the cel-
lular barrier. Therefore, probiotic use improves the body’s defenses by triggering an im-
mune response, according to the pathological state, and promoting a balance between pro-
and anti-inflammatory cytokines that are secreted by activated immune cells. Probiotics
hence act as a non-specific adjuvant to the innate immune response [50]. There is evidence
that probiotics promote the production of some cytokines, including IL-10, transforming
growth factor (TGF)-β, IL-12, and INF-γ, which regulate the immune response and reduce
allergic inflammation [10].
Many studies have shown that the gut microbiota and probiotic intake can support
maturation of the immune system during the first years of life due to different physiological
and metabolic reactions in the host. The most promising probiotics in terms of immune
system development are those belonging to the genera Lactobacillus and Bifidobacterium [6].
The effects of probiotics are dose- and strain-dependent [51,52] and may be influenced
by age-specific functions, such as the maturity of the host’s intestinal barrier. It was
suggested that the perinatal period may represent a window of opportunity for effective
probiotic intervention in allergic diseases [53]. In the first stage of life, the microbiota is still
developing, so the administration of probiotics leads to a proper microbial colonization and
results in a greater effectiveness in the prevention and treatment of different diseases [17].
The immune effects of probiotics, which are primarily mediated through the innate immune
system, include the promotion of epithelial integrity, intestinal permeability, and mucus
production through the production of anti-inflammatory cytokines and tolerogenic CD103+
dendritic cells, in addition to the promotion of the differentiation and proliferation of
regulatory T cells, the inhibition of the Th2 cell response, and an increased release of
IgA from plasma cells [54,55]. The therapeutic potential of probiotics in allergic diseases
is mediated by various mechanisms of action, such as the modulation of the immune
response, competitive inhibition of invasive flora in the gut, modification of pathogenic
toxins and host products, and an increased epithelial barrier function [41].
Lactobacillus reduces proinflammatory responses by regulating nuclear factor kappa
B (NF-κB) signaling. Probiotics also promote the maturation of dendritic cells (DCs) into
anti-inflammatory cytokines, such as IL-10. In addition, human monocyte-derived DCs
can release IL-10 when treated with probiotics, thus triggering the differentiation and
survival of Tregs [23]. Bifidobacterium animalis and Bifidobacterium longum induce the release
of interferon gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α) by DCs, while
only Bifidobacterium bifidum can activate Th17 cells through the release of IL-17. Different
studies have indicated that probiotics can modulate the Th1/Th2 balance and, consequently,
prevent inflammatory diseases, such as allergies [23].
3.3. Use of Probiotics in Allergic Diseases
The increased prevalence of allergies, such as eczema, may be due to alterations
in the gut microbiota in early life, such as a reduced abundance of the Proteobacteria phy-
lum and the general Bifidobacterium, Akkermansia, Faecalibacterium, and Lachnospira [52,56].
For example, an association has been described between gut colonization with Clostridium
difficile and allergies in children. Various studies have shown that children with atopic
dermatitis have a less diverse gut microbiota [56,57] and lower Bifidobacterium levels [57]
than healthy children. In allergic children, higher counts of Staphylococcus aureus and Enter-
obacteriaceae and lower Bifidobacterium counts were found than in healthy children [58].
In addition, a lower colonization of enterococci during the first month of life and of Bifi-
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dobacterium during the first year of life have been found in infants with allergies, compared
to non-allergic infants [58].
It has been proposed that probiotics could potentially restore intestinal homeostasis
and prevent or alleviate allergies by interacting with the intestinal immune cells [51].
Moreover, symbiotics, which are a synergistic combination of probiotics and prebiotics,
have proven beneficial for different allergic conditions, for example, by reducing asthma-
like symptoms and the use of asthma medications [59].
Probiotics are useful for the modulation of allergic diseases, as they stimulate the lev-
els of IgA in the mucosa and the T and B cells of the immune system [23]. The results
of different studies examining the influence of probiotics on allergic diseases have been
contradictory, and as a result, few practical recommendations as to the use of probiotics
in allergic diseases have been established [60]. It is important to note that, due to multiple
factors, the results vary between studies (Figure 1). The impact of probiotics on humans is
highly variable between individuals. For example, a recent study found that individuals
with a healthier gut microbiota composition responded in a better way than other indi-
viduals to the administration of probiotics [61]. This result is logical, because the action
of probiotics depends on several factors, including colonization resistance, acid and short
chain fatty acid production, the competitive exclusion of pathogens, and bacteriocin pro-
duction, which can influence probiotic persistence [62,63]. Zmora et al. [64] demonstrated
that persistent personalized gut mucosal resistance to commercial probiotics is associated
with unique host and microbiome features. For example, a probiotic’s colonization can be
affected by an under-representation of specific carbohydrate-utilization genes in the gut,
thus preventing the complex metabolization of polysaccharides by the probiotic bacte-
ria [62]. Thus, the efficacy of probiotics is dependent on both the microbial species or strain
and its derived metabolites and byproducts (commonly named as postbiotics), as well as
the number of probiotic cells and type of probiotic carrier [27].
Figure 1. Factors that could explain the varied effects of probiotics uncovered by different studies.
Previous studies have found that supplementation with various probiotic preparations
can balance the intestinal microbiota, regulate the immune system, and reduce allergies.
Further, these studies have explored new strains of probiotics, probiotic genomic char-
acteristics, and the in vivo mechanisms of action, formulation processes, and safety of
probiotics [65,66]. Currently, studies are attempting to identify protective factors that
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regulate the immune system and allow for tolerance of different allergens in a specific
way. One of the most studied probiotics is Lactobacillus GG, which is frequently studied
in connection with the management of AD, although the results have been quite incon-
sistent [8]. Further, Lactobacillus were able to reduce allergic symptoms and to reduce
morbidity in children [67].
Taniuchi et al. [68] demonstrated that a Bifidobacterium species was effective in the treat-
ment of cow’s milk hypersensitivity in infants with atopic dermatitis. In addition, Enomoto
et al. [69] demonstrated that prenatal and postnatal supplementation with two species
of Bifidobacterium reduced the risk of developing eczema and atopic dermatitis in infants.
These differences disappeared at 10 months of age, highlighting that the early stage micro-
biota is particularly important for regulating allergies in children.
Two systematic reviews and meta-analyses show that probiotic supplementation be-
fore and after birth can prevent allergic diseases, particularly eczema [70,71]. On the other
hand, when probiotics are administered only after birth, they may not be effective in pre-
venting allergic diseases [71,72].
Many animal studies, mainly in mice, in which different probiotics in isolation or
mixtures of them were used to treat or prevent allergic diseases, show an effect. Obviously,
experimental animals differ widely from humans in key aspects, such as the gut microbiota
composition, immune function, or metabolism [45]. Thus, extrapolating the results obtained
from animal models to humans may not be valid and should always be considered as
preliminary or limited.
The probiotics most often used in these studies are the Lactobacillus and Bifidobacterium
genera and, to a lesser extent, Enterococcus [73]. The use of Enterococcus as probiotics
presents some intrinsic risks that makes them poorly suited to use as probiotics, especially
the E. faecium and E. faecalis species. As opportunistic pathogens, both enterococci possess
an array of virulence factors and antibiotic resistance determinants, which render them
controversial. Even in avirulent enterococci, when they reach the intestinal tract, they
can interact with endogenous enterococci and other commensals that could lead to bi-
directional genetic exchange [65,66].
In terms of allergies, the most studied are those related to the airways, such as asthma,
but also atopic dermatitis [74,75] and food allergies [6,76]. The beneficial effects of probiotics
on allergies include a reduction in hyperreactivity and inflammation due to the presence of
allergens, a decrease in interleukins and eosinophils, and a reduction in TNF and INF, etc.
In addition to the animal studies, there have also been many studies with humans,
especially children (Table 1). As in the studies with mice, in this case, the probiotics
most often used were of the genera Bifidobacterium and Lactobacillus, or mixtures of them.
To a lesser extent, Propionibacterium [77] or Escherichia coli and Enterococcus faecalis [8] were
used, and these probiotics were administered in doses of 107 to 1010 colony-forming units
(CFU)/day. Today, the consensus statements consider a number of viable cells of 1 ×
109 CFU/day in food and food supplements as the minimum number to be effective [48].
To a lesser extent, food and respiratory allergies have been studied. The beneficial effects
found in these studies were a reduction in inflammatory cells, decrease in interleukins,
reduction in TNF and INF, and, above all, reduction in symptoms and improvement
in the quality of life of people suffering from these allergies. Researchers, such as Simpson
et al. [78] and Loo et al. [79], followed up their studies for several years to observe the effects
of probiotics over time. Studies with a follow-up of 5 years or longer show that the greatest
protective effect of probiotics against AD occurs in early childhood and that this effect is
less likely to be sustained until school age [78].
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Table 1. Use of probiotics to treat or prevent allergic diseases in infants.
Type of Study Probiotic Dosage and Time of Exposure Allergic Disease Main Findings Reference
Randomized, double-blind study
with 27 infants with atopic disease
Bifidobacterium lactis Bb-12 and
Lactobacillus rhamnosus GG (LGG)
Oral administration of 3 × 108 CFU of LGG and
109 CFU of B. lactis for 4 weeks Atopic eczema
After 2 months, a significant improvement in the skin condition
occurred in the probiotic group. The Scoring Atopic Dermatitis
(SCORAD) and concentration of soluble CD4+ decreased




study with 58 children
Lactobacillus rhamnosus 19070-2 and
Lactobacillus reuteri DSM 122460 A dose of 10
10 CFU twice daily for 6 weeks Atopic dermatitis
The duration of eczema decreased during probiotic
administration. The treatment response was more pronounced
in allergic patients, and the SCORAD score decreased
[81]
Randomized, double-blind,
placebo-controlled study with 230
infants with suspected cow’s milk
allergy (CMA)
LGG, L. rhamnosus LC705, B. breve
Bb99 and Propionibacterium
freudenreichii ssp shermanii JS
Oral administration of LGG (5 × 109 CFU) or
a mixture of LGG (5 × 109 CFU), L. rhamnosus
LC705 (5 × 109), B. breve Bb99 (2 × 108),
and Propionibacterium freudenreichii spp. shermanii
JS (2 × 109) twice daily for 4 weeks.
Atopic dermatitis related
to cow’s milk allergy
Treatment with LGG may alleviate symptoms of atopic eczema
and/or dermatitis syndrome in IgE-sensitized infants [77]
Randomized, double-blind,
placebo-controlled study with 56
children
Lactobacillus fermentum VRI-033 PCC 1 × 109 CFU twice daily for 8 weeks Atopic dermatitis
A reduction in the SCORAD index was seen
in the probiotic-treated group. At the end of the study, more




study with 59 children with AD
L. rhamnosus and B.
lactis A dose of 2 × 10
10 CFU daily for 12 weeks Atopic dermatitis A combination of L. rhamnosus and B. lactis improved atopicdermatitis only in food-sensitized children [83]
Randomized, double-blind,
placebo-controlled study with 50
infants
L. rhamnosus Lrh and LGG
Administering 1, 5, 25 and 125 mL of cow’s milk
formula at 30 min intervals (5 × 109 CFU/mL
formula)
Atopic dermatitis related
to cow’s milk allergy
No clear effects were seen on the SCORAD, sensitization,
inflammatory parameters, or cytokine production [84]
Randomized trial with newborns of
231 women with allergies Lactobacillus acidophilus LAVRI-A1 3 × 10
9 CFU/day for the first 6 months of life Atopic dermatitis
Atopic dermatitis rates were similar in the probiotic and
placebo groups. At 12 months, the rate of sensitization was
significantly higher in the probiotic group
[85]
Randomized, double-blind,
placebo-controlled study with 193
infants diagnosed with cow’s milk
allergy (CMA)
Lactobacillus casei CRL431 and
Bifidobacterium lactis BB-12




Supplementation with Lactobacillus and Bifidobacterium
in an extensively hydrolyzed formula did not accelerate cow’s
milk tolerance in infants with CMA
[86]
Double-blind, placebo-controlled,
randomized trial with 253 infants
B. longum BL999 and L. rhamnosus
LPR
Oral supplementation with 1 × 107 CFU/g/day
of B. longum and 2 × 107 CFU/g/day of L.
rhamnosus for the first 6 months
Atopy and eczema No significant effect on the prevention of eczema or allergensensitization in the first year of life [87]
Double-blind, placebo-controlled,
randomized trial with 179 infants Lactobacillus F19 1 × 10
8 CFU/day for 4–6 months Eczema
The cumulative incidence of eczema at 13 months was lower
in the probiotic group. At 13 months, the INF-y/IL-4 ratio was
higher in the probiotic group. No differences in serum
concentrations of IgE
[88]
Randomized, double-blind trial of
children from 415 mothers
LGG, B. animalis ssp. lactis
Bb-12 and L. acidophilus La-5
Milk contained 5 × 1010 CFU/day of L.
rhamnosus and Bb-12. 5 × 109 CFU of L.
acidophilus for 4 months, from 36 weeks of
gestation to 3 months postnatally
Atopic dermatitis and
asthma
In the probiotic group, the cumulative incidence of atopic
dermatitis was reduced but there was no effect on sensitization [89]
Randomized, double-blind study
with 39 infants with AD LGG A daily intake of 3.4 × 10
9 CFU for 3 months Atopic dermatitis
The proportions of IgA- and IgM-secreting cells decreased
in the probiotic group, and the proportions of CD191+ and
CD27+ B cells increased
[90]
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Table 1. Cont.
Type of Study Probiotic Dosage and Time of Exposure Allergic Disease Main Findings Reference
Randomized, placebo-controlled trial
with 606 newborns
Escherichia coli DSM 17252 and
Enterococcus faecalis DSM 1644
Oral bacteria lysate containing heat-killed
nonpathogenic 1.5–4.5 × 107 bacteria/mL (3 ×
0.7 mL/day)
Atopic dermatitis
A significant effect was observed in a subgroup of the probiotic
group with single heredity for atopy, which was most
pronounced for infants with atopic fathers
[8]
Double-blind, placebo-controlled,
randomized parallel study with 100
children
Mixture of L. casei, L. rhamnosus, L.
plantarum, and B. lactis
Oral administration at 2 × 109 CFU in each strain,
twice daily for 6 weeks Atopic dermatitis
The probiotic mixture did not suppress the growth of other
strains, but no differences in clinical improvement were seen




study with 2020 children
L. paracasei GMNL-133 and/or L.
fermentum GM090
2 × 109 CFU/day of L. paracasei, L. plantarum, or
4 × 109 CFU of a mixture for 3 months Atopic dermatitis
Children given either probiotics alone or a mixture of both
showed a decrease in the severity of atopic dermatitis scores.
Lower test scores were also recorded for people with skin




double-blind study with 159
newborns
LGG 1010 CFU/day for the first 6 months of life Eczema and asthma The estimated cumulative incidence of eczema and asthma waslower in the probiotic group at 2 years of age [92]
Prospective, double-blind,
placebo-controlled, randomized
study with 40 children
B. longum BB536, Bifidobacterium
infantis M-63, and B. breve M-16 V
Oral supplementation containing B. longum
BB536 (3 × 109 CFU), B. infantis M-63 (1 × 109
CFU), and B. breve M-16 V (1 × 109 CFU) as
powder in a 3 mg sachet. Administered every
day for 8 weeks
Seasonal allergic rhinitis
and intermittent asthma
A significant improvement of symptoms and quality of life
in the probiotic group [67]
Double-blind, 2-arm,
placebo-controlled study with 50
children with AD
B. lactis CECT 8145, B. longum
CECT7347, and L. casei CECT 9104
109 CFU/day of a mixture of the 3 probiotic
strains Atopic dermatitis
A reduction in IL-4, IL-5, and IL-13 and a decreased activity of
Th2 in the probiotic group. The SCORAD index and use of




with 1099 very preterm infants
B. infantis BB-02, Streptococcus
thermophilus TH-4, and B. lactis BB-12
A combination of B. infantis BB-02 (300 × 106
CFU), S. thermophilus TH-4 (350 × 106 CFU),
and B. lactis BB-12 (350 × 106). Total: 1 × 109
CFU per 1.5 g in a powder once daily, until




There was no difference in eczema incidence between the two
groups. Additionally, the incidence of atopic eczema, food
allergy, wheezing, and atopic sensitization were similar in both
groups
[52]
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As shown in (Table 1), most studies employed Lactobacillus or Bifidobacterium spp. as
the probiotics. However, other bacterial species were also employed, such as Propionibac-
terium freudereichii ssp shermanii JS [77], Escherichia coli DSM 17252, and Enterococcus faecalis
DSM 1644 [8] or Streptococcus thermophilus TH-4 [52]. The use of opportunistic pathogens,
such as Escherichia coli or Enterococcus faecalis in infants, is controversial due to the above-
mentioned risks related to genetic exchange of virulence factors and antibiotic resistance
determinants [65,66]. In all but three cases [67,86,92], the probiotics were employed to
alleviate symptoms or prevent skin allergic diseases.
The effects obtained are controversial, because in several cases [41,52,85–87], no sig-
nificant differences were found between the probiotic- and placebo-treated groups. One
of the studies that did not find any significant change was a multicenter study trial with
more than 1000 infants. For the cases in which significant effects were found, in most cases,
the beneficial effects were slight, and in two studies, the beneficial effects were limited to
specific child subgroups [8,83].
The results found regarding probiotic usage in adults and in both mother–child pairs
with the aim of treating or prevent allergic diseases can be found in (Table 2).
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Table 2. Use of probiotics to treat or prevent allergic diseases in adults and mother–infant pairs.
Type of Study Probiotic Dosage and Time of Exposure Allergic Disease Main Findings Reference
Double-blind, randomized,
placebo-controlled study with 159 mothers
with allergic diseases and their infants
Lactobacillus rhamnosus GG
(LGG) 1 × 10
10 CFU daily for 2–4 weeks Atopic eczema, asthma,and allergic rhinitis
The incidence of eczema in the probiotic group was halved.
The concentrations of total immunoglobulin (Ig) E and




placebo-controlled trial with 44 adults Bifidobacterium longum BB536 5 × 10
10 CFU twice daily for 13 weeks Japanese cedar pollinosis(JCPsis)
B. longum reduced severe symptoms and medication and
decreased nasal blockage in rhinorrhea, and composite
scores. Improvements in all symptoms
[58]
Randomized trial with newborns of 231
women with allergy
Lactobacillus acidophilus
LAVRI-A1 3 × 10
9 CFU/day for the first 6 months of life Atopic dermatitis
Atopic dermatitis rates were similar in the probiotic and
placebo groups. At 12 months, the rate of sensitization was
significantly higher in the probiotic group
[85]
Double-blind, randomized,
placebo-controlled study with 232 mothers L. reuteri ATCC 55730
1 × 108 CFU/day from gestational week 36
until delivery. Their babies then continued
with the same product from birth until 12
months
Eczema
The cumulative incidence of eczema was similar in the two
groups. The probiotic group had less IgE-associated,
and skin prick test reactivity was also less common
[56]
Randomized, double-blind,
placebo-controlled study with 2 parallel
groups of 1223 pregnant women
LGG, L. rhamnosus LC705,
Bifidobacterium breve Bb99, and P.
freudenreichii spp. shermanii JS
Oral administration of LGG (5 × 109 CFU), L.
rhamnosus LC705 (5 × 109), B. breve Bb99 (2 ×
108), and Propionibacterium freudenreichii spp.
shermanii JS (2 × 108) twice daily for 2 to 4
weeks before delivery. Their infants received
the same probiotics (+ prebiotics) once daily




Administration of these probiotics significantly prevented
eczema and atopic eczema [94]
Placebo-controlled, double-blind study with
171 mother–infant pairs LGG and B. lactis Bb12
1010 CFU/day of each probiotic from the first
trimester of pregnancy to the end of exclusive
breastfeeding
Atopy (eczema)
The concentration of TGF-b2 was higher in colostrum from
dams supplemented with probiotics. This supplementation
produced a protective effect against sensitization in infants at
a high hereditary risk
[95]
Two-center, double-blind, randomized,
placebo-controlled trial with 512 pregnant
women and 474 infants
L. rhamnosus HN001 and
Bifidobacterium animalis spp. lactis
HN019
Two treatment groups: 6 × 109 CFU/d of L.
rhamnosus or 9 × 109 CFU/d of B. animalis
from 35 weeks of gestation until 6 months
in pregnant women and from birth to 2 years
in infants
Eczema and atopy
Supplementation with only L. rhamnosus reduced




prospective study with 105 pregnant women LGG
5 × 109 CFU twice daily. Started 4–6 weeks
before expected delivery until a postnatal
period of 6 months
Atopic dermatitis There was no significant difference between the probioticgroup and placebo groups [97]
Randomized, double-blind,
placebo-controlled trial with 112 pregnant
women
Bifidobacterium bifidum BGN4, B.
lactis AD011, and L. acidophilus
AD031
Mixture of probiotics (1.6 × 109 CFU/day of
each probiotic) for 4–8 weeks before delivery
until 6 months after delivery
Eczema
The prevalence of eczema in the probiotic-added group was
lower. The cumulative incidence of eczema during the first
12 months was reduced in the probiotic group. No difference
in the serum total IgE level or sensitization to food allergens
[7]
Double-blind, randomized,
placebo-controlled study with 156 pregnant
women
B. bifidum W23 and B. lactis W52
1 × 109 CFU/day of each strain during the last
6 weeks of pregnancy and postnatally for 12
months to their offspring
Eczema
The prevalence of eczema during the first 3 months of life
was significantly lower in the probiotic group.
The cumulative incidence was also lower in the probiotic
group
[98]
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Table 2. Cont.
Type of Study Probiotic Dosage and Time of Exposure Allergic Disease Main Findings Reference
Randomized, double-blind trial of children
from 415 mothers
LGG, B. animalis ssp. lactis
Bb-12, and L. acidophilus La-5
Milk contained 5 × 1010 CFU/day of L.
rhamnosus and Bb-12. 5 × 109 CFU of L.
acidophilus for 4 months, from 36 weeks of
gestation to 3 months postnatally
Atopic dermatitis and
asthma
In the probiotic group, the cumulative incidence of atopic
dermatitis was reduced, but there was no effect on
sensitization
[89]
Double-blind, placebo-controlled study with
36 subjects with allergic rhinitis
L. rhamnosus GR-1 and
Bifidobacterium adolescentis
7007-05
Added L. rhamnosus at 4% and B. adolescentis at
10% of final milk volume Rhinitis
Serum IL-10 and IL-12 levels were increased in the probiotic
group at the end of the grass pollen season. Additionally,
the serum TFG-β levels were higher during the ragweed
season
[99]
Randomized controlled trial with 250
pregnant women LGG
1.8 × 1010 CFU/day from 36 weeks of
gestation until delivery Eczema
Prenatal probiotic treatment was only associated with
decreased breast milk soluble CD14 and IgA levels [100]
Randomized, double-blind,
placebo-controlled study Lactobacillus plantarum CJLP133 0.5 × 10
10 CFU twice a day for 12 weeks Atopic dermatitis
SCORAD scores were lower with probiotic administration.
Additionally, the total eosinophil counts were significantly




study of 241 mother–infant pairs
L. rhamnosus LPR, B. longum
BL999, and Lactobacillus paracasei
ST11
Combination of L. rhamnosus and B. longum or
L. paracasei and B. longum. Daily dose for each
probiotic (1 × 109 CFU) for 2 months before
delivery and during the first 2 months of
breastfeeding. The infants were followed for
24 months
Eczema
The risk of eczema was reduced in infants of mothers




placebo-controlled study with 191 pregnant
women
LGG 1 × 10
10 CFU/day from the second trimester
of pregnancy Atopic diseases
No significant effects of prenatal and postnatal probiotic
supplementation on sensitization, development of allergic
diseases, and maternal IgE levels. The allergic symptoms
improved in the probiotic group
[103]
Double-blind, parallel-group,
placebo-controlled comparison with 49 AD
patients
L. acidophilus L-92 20.7 mg/day for 8 weeks Atopic dermatitis
This probiotic contributes to the suppression of
Th-2-dominant inflammation and reduces atopic dermatitis
symptoms in adults
[104]
Randomized controlled study with 415
pregnant women
LGG, B. animalis spp. Lactis
Bb-12, and L. acidophilus La-5
Daily dose of LGG (5 × 1010 CFU), B. animalis
spp. Lactis Bb-12 (5 × 1010 CFU), and L.
acidophilus La-5 (5 × 109 CFU) from 36 weeks
of gestation to 3 months postnatal
Atopic dermatitis
Supplementation with a combination of these probiotics
reduced the proportion of Th22 cells. However,
the proportion of Tregs, Th1, Th2, and Th17 cells and
the Th1/Th2 ratio in the offspring were not affected
[105]
Double-blind, placebo-controlled, parallel,
randomized clinical study with 173
participants
Lactobacillus gasseri KS-13, B.
bifidum G9-1, and B. longum
MM-2
Each capsule (350 mg) contained L. gasseri
KS-13 (1.2 billion CFU), B. bifidum G9-1 (0.15
billion), and B. longum MM-2 (0.15 billion)
Rhinoconjunctivitis-
specific
An improvement in the rhinoconjunctivitis-specific quality
of life during allergy season was seen in the probiotic group [106]
Randomized, double-blind,
placebo-controlled study with 22 AD
subjects
L. plantarum IS-10506 1010 CFU/day for 12 weeks Atopic dermatitis
Reduction in clinical symptoms in AD children and
decreased SCORAD and levels of serum IgE, IL-4, and IL-17.
The probiotic acted through the downregulation of
the Th2-adaptive immune response
[107]
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As shown in (Table 2), most studies employed probiotics against skin allergic diseases,
but they were also used against allergic rhinitis or asthma [55,89,94,99], Japanese cedar
pollinosis [58], food allergies [94], and rhinoconjunctivitis [106]. All studies employed
Lactobacillus or Bifidobacterium spp. as the probiotic strains, with only one exception, where
mixed Propionibacterium freudereichii ssp shermanii JS were employed [94]. Unlike in the case
of infants, in the case of adults or mother-infant pairs, the administration of probiotics
had positive effects, except in two cases [98,104]. In these two cases, where Lactobacillus
rhamnosus GG were employed in pregnant women, no beneficial effects were found.
It is important to note that probiotics are considered safe due to their widespread use
in food and dairy products, even more so than a hundred years ago [23]. Studies such as
systematic reviews and meta-analyses show that the use of probiotics is safe in preterm
infants [108]. However, several risks can be associated with probiotic therapy in the clinical
field and in vulnerable target groups, such as pregnant women, infants, and immunod-
eficient subjects [23]. Medical studies have shown that, although uncommon, the use of
probiotics may have some side effects, such as the spread of inappropriate resistance genes
in intestinal microbial populations, virulence factors in probiotic microbial strains, translo-
cation to tissues and blood, an inflammatory response, and infections [27,109]. Commercial
probiotics have also been found to contain live microorganisms not listed on their labels,
which can be dangerous to an individual [110,111]. In fact, a premature infant has been
reported to have died from fulminant gastrointestinal mucormycotic due to fungal con-
tamination of a probiotic supplement used. Therefore, it is also important to use probiotics
with some caution [110,111].
In addition, it should be noted that some of the studies collected have not clearly
shown the effects of probiotics in treating allergies [52,84,87,97]. The studies that did
not find beneficial effects on humans included those that applied Lactobacillus [82,95],
mixes with Bifidobacterium [87], or Streptococcus [52] to preterm infants [52], children [52,84],
and pregnant women [97]. The only link between these studies is that in all cases, probiotics
were used for the treatment or prevention of atopic dermatitis, so it seems that in this
pathology, the use of probiotics seems only minorly effective for this purpose.
Probiotics can be taken as pharmaceutical preparations or as functional foods, gener-
ating wider acceptance among consumers, mainly as fermented foods [49]. As the intake
of functional foods shows a better consumer acceptance than pharmacological presenta-
tions, there is potential for foods that are consumed regularly when they are converted to
functional foods [49]. It is true that interest is increasingly focused on the potential appli-
cations of food-derived products that can be used as tools to prevent or delay the onset
of a health problem, in this case allergies. This has given rise to nutraceuticals, which
are defined as “the phytocomplex if derived from a food of plant origin, and as the pool
of secondary metabolites if derived from a food of animal origin, concentrated and ad-
ministered in the most appropriate pharmaceutical form”. This does not stop here, but
nanotechnology has enabled progress to be made towards nanonutraceuticals, which have
advantages due to their remarkable properties and versatility. Alternatively, nanonization
strategies for probiotics and the usefulness of nanoprobiotics in releasing encapsulated
bacteria and enhancing their absorption in the gastrointestinal tract are being explored,
which may be of great interest in the treatment of allergies [112].
There are also studies showing that the intake of fermented foods, such as fermented
yeast, galactooligosaccharides, or fructooligosaccharides, can improve the symptoms of
some allergies, such as asthma or eczema, by reducing oxidative stress and inflamma-
tion [113–115]. This suggests that the combined administration of probiotics and prebiotics
could be useful for alleviating the symptoms of allergic patients.
4. Limitations, Conclusions, and Future Trends
Some of the studies have limitations, e.g., the reduced sample size, the randomization
process, and the small number of bacterial groups used. In some cases, the probiotic
dosage employed is below the minimum consensus (109 UFC/day) for the appropriate use
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of probiotics. Thus, the results obtained in the studies that did not reach the minimum
consensus limit of the appropriate use of probiotics are of doubtful validity.
“Probiotic” means “for life”, and probiotics are defined as “live microorganisms
that, when being administered in appropriate doses, confer a benefit to the health of
the host”, and although the use of most probiotics is generally safe, the use of some
bacterial opportunistic pathogens, such as Enterococcus or Escherichia, is controversial and
should be avoided, especially in vulnerable collectives, because they can interact with
endogenous commensal pathogens with bi-directional genetic exchange. Previous studies
have shown that, although uncommon, the use of probiotics may have some side effects.
This review has collected different published studies that show the beneficial effects
of using probiotics to treat allergic diseases. No clear beneficial effects were found in chil-
dren, because in several studies, no significant differences were found between probiotic-
and placebo-treated groups. Even considering that probiotics do not cure allergies, their
administration can reduce the morbidity and the duration of allergy symptoms. An alter-
native to the administration of probiotics in supplement form would be to consume them
in functional foods, which are foods produced not only for their nutritional characteristics,
but also to fulfil a specific function, such as improving health and/or reducing the risk of
disease, as these would be more acceptable to consumers than pharmacological presenta-
tions and easier to consume. Another increasingly emerging way would be in the form of
nanoprobiotics.
While many studies have been conducted, more clinical trials in humans are needed to
observe the true effects of probiotic consumption on allergic diseases, but this review gives
an idea of the great benefits that are likely to result from the use of probiotics in the treat-
ment of allergies and the administration of probiotics alongside other treatments, thus
reducing the morbidity of people living with allergies. Additionally, the efficacy of pro-
biotics is dependent also on factors such as the composition and activity of the subject’s
intestinal microbiota and the derived metabolites and byproducts synthesized by the pro-
biotic species. Thus, prior knowledge of the state of the subject’s intestinal microbiota prior
to the use of the probiotic agent would be advisable to improve its effectiveness.
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